Tryptophan

SCOPE — this is the whole of the adult posology in the fetched UK SPC; the product has a single oral presentation and the SPC gives no separate regimen for any other indication. §4.2 VERBATIM, in full: 'Adults — The usual dose is two capsules, three times daily; for some patients, up to 6g L-tryptophan may be required.' || THE COUNT IS CONVERTIBLE BECAUSE THE PRODUCT NAME PINS THE STRENGTH: the fetched product is 'Optimax 500mg Capsules', so two capsules = 1 g L-tryptophan per dose and three doses = 3 g daily. The milligram figures shown are that arithmetic on the pinned 500 mg strength — the SPC itself states the dose only as a capsule count. || ON THE 6 g FIGURE: the SPC phrases it as 'may be required' rather than as a hard ceiling, but it is the only upper figure stated anywhere in the fetched text, it is the same product, route and indication, and no other maximum appears. It is reproduced verbatim in maxDose so the wording travels with the number. Note that 6 g/day is twice the usual 3 g/day regimen. || ELDERLY, §4.2 verbatim: 'A lower dose may be appropriate, especially where there is evidence of renal or hepatic impairment.' No figure is attached to 'lower'. || ⚠️ §4.5 IS TRUNCATED at the source-fetch limit, cut off mid-sentence at 'Where L-tryptophan is combined with MAO Inhibitors such as phenelzine, moclobemide and […]'. The MAOI advice this page's interaction list depends on was therefore NOT retrieved, and neither was any dose reduction that sentence may specify. §4.4 does retrieve the serotonin-syndrome warning: 'The possible interaction between L-tryptophan and 5HT reuptake inhibitors could lead to the serotonin syndrome characterised by a combination of agitation, restlessness and gastro-intestinal symptoms including diarrhoea. Combinations with 5HT reuptake inhibitors should only be used with care.' || ADMINISTRATION TIP from §4.8: 'In some patients, L-tryptophan may cause a slight feeling of nausea which usually disappears within 2 or 3 days. Such nausea can be minimised by giving L-tryptophan after food.' || THE US CROSS-CHECK LABEL IS NOT USABLE: 'DIRECTIONS: 10 drops orally, 3 times a day' is a drop count with no strength stated anywhere in the fetched text, so it cannot be converted to a dose and is not published. It is also a different dosage form from the UK capsules. || The fetched sections do not state the licensed indication; §4.4 is written entirely around depression, antidepressant therapy and suicidality, consistent with this page's 'treatment-resistant depression — specialist psychiatry' framing, but the indication itself is unsourced in this bundle. || PAEDIATRIC: paedDose is null because the SPC establishes none. §4.2 verbatim: 'Paediatric population — The safety and efficacy of Optimax in children have not been established.' The US drops label's line 'Consult a physician for use in children under 12 years of age' carries no strength and no dose, so it adds nothing. Any paediatric use must be checked against a children's formulary and specialist advice.